• MicroPort NeuroScientific’s Artemis Dream self-expanding intracranial rapamycin-eluting stent entered China NMPA’s innovative device “Green Path” special review program.
• The designation is expected to shorten the registration review timeline, accelerating potential market launch for intracranial arterial stenosis treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microport Neuroscientic Corporation published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260730-12261115), on July 30, 2026, and is solely responsible for the information contained therein.